These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35950406)

  • 1. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
    Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
    J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
    Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Denmeade S; Lim SJ; Isaaccson Velho P; Wang H
    Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
    Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
    Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
    van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
    Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
    Anticancer Res; 2023 Jan; 43(1):429-436. PubMed ID: 36585210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
    Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
    Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
    Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
    Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
    Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
    Caputo SA; Hawkins M; Jaeger EB; Fleming W; Casado C; Manogue C; Huang M; Lieberman A; Light M; Sussman IP; Miller P; Barata PC; Lewis BE; Layton JL; Ledet EM; Antonarakis ES; Sartor O
    Prostate; 2023 Jun; 83(9):879-885. PubMed ID: 36959766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
    Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.